Latest News and Press Releases

CANTON, Mass., July 06, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that management will present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference on...

CANTON, Mass., June 27, 2016 (GLOBE NEWSWIRE) -- EY announced that Collegium’s CEO, Michael Heffernan, received the EY Entrepreneur of the Year® 2016 Award in the Life Sciences and Healthcare...

CANTON, Mass., June 22, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced positive topline results from a clinical study evaluating Hydrocodone DETERx® as a...

CANTON, Mass., June 20, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced the commercial launch of Xtampza® ER (oxycodone) extended-release (ER) capsules in the...

CANTON, Mass., June 13, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced the election of John A. Fallon, M.D. to the Board of Directors. "John’s broad-based...

CANTON, Mass., June 02, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that it will present data on the use of Xtampza ER, an extended-release oral...

CANTON, Mass., June 02, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that management will present at the following investor conferences in June:Jefferies...

CANTON, Mass., May 23, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) will host Investor Day on Wednesday, May 25th at the St. Regis Hotel in New York City (2 East 55th...

CANTON, Mass., May 11, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced today the licensing of the U.S. rights to develop and commercialize ONSOLIS® (fentanyl buccal...

CANTON, Mass., May 11, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that it will present data on the use of Xtampza™ ER, an extended-release oral...